Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
复制标题
DOI：
10.1160/th13-01-0004
复制
发表时间：
2013-07-01
影响因子：
6.7
通讯作者：
Sharma, Samin K.
中科院分区：
文献类型：
--
作者：
Baber, Usman;Bander, Jeffrey;Sharma, Samin K.
同时患有慢性肾脏疾病(CKD)和糖尿病(DM)的患者与那些患者相比，血栓事件的风险更高。只有一个异常。这是否可以归因于CKD和DM患者的血小板反应性改变，目前尚不清楚。我们前瞻性地研究了438名接受经皮冠状动脉介入治疗(PCI)的氯吡格雷初治患者。在服用600 mg氯吡格雷后4~6h进行血小板功能检测。使用VerifyNow系统评估血小板反应性，并以P2Y12反应单位(PRU)表示。高残留血小板反应性(HRPR)定义为PRU>；230。根据有无慢性肾脏病和糖尿病患者被分成四组。无慢性肾脏病组、糖尿病组、单纯慢性肾脏病组、单纯慢性肾脏病组、合并糖尿病组分别为201.6±96.3、220.5+/-101.1、254.9+/-106.7、275.0+/-94.5(P
Patients with both chronic kidney disease (CKD) and diabetes mellitus (DM) are at increased risk for thrombotic events compared to those. with one abnormality alone. Whether this can be attributed to changes in platelet reactivity among those with both CKD and DM is ' unknown. We prospectively studied 438 clopidogrel-naive patients; undergoing percutaneous coronary intervention (PCI). Platelet function tests were performed 4-6 hours after loading with 600 mg of clopidogrel. Platelet reactivity was assessed using the VerifyNow system and expressed as P2Y12 reaction units (PRU). High residual platelet reactivity (HRPR) was defined as PRU > 230. Patients were categorised into four groups by the presence or absence of CKD and DM. Among those without CKD or DM (n=166), DM alone (n=150), CKD; alone (n=60) and both CKD and DM (n=62) the mean PRU levels were 201.6 +/- 96.3, 220.5 +/- 101.1, 254.9 +/- 106.7 and 275.0 +/- 94.5, respectively (p